← Trials/Trial dossier/NCT06363487

OxSENSE

CompletedPhase NA

Semaglutide and Cognition in Healthy Volunteers

Effects of Single-dose Semaglutide on Cognition and Energy in Healthy Volunteers

Lead sponsor

University of Oxford

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18-30•Healthy volunteers

Primary endpoints

•Reward (learning)•Reward (effort-based)•Reward (primary)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06363487

Org study IDR87970/RE001

Timeline

Milestones

Study first posted2024-04-12actual

Study start2024-06-06actual

Primary completion2024-12-11actual

Study completion2024-12-11actual

Last update posted2025-06-06actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Male or female

•Aged from 21 to 55 years

•Body Mass Index (BMI) from 18 to 30 (because our main outcomes involve cognitive and energy measures, this decision regarding the BMI range has been taken with the purpose of including a more homogeneous sample of healthy participants in terms of baseline cognitive and energy levels)

•Sufficiently fluent English to understand and complete the tasks

•Participant is willing and able to give informed consent for participation in the research

•Not currently taking any regular medications (except the contraceptive pill)

Exclusion criteria

•Currently on any regular prescribed medications (except the contraceptive pill), unless unlikely to compromise safety or affect data quality in the opinion of the medical supervisor according to clinical judgement

•History of, or current significant psychiatric illness in the opinion of the medical supervisor according to clinical judgement

•Current alcohol or substance misuse disorder (<6 months)

•Current moderate or severe dyslexia

•History of, or current significant medical illness in the opinion of the medical supervisor according to clinical judgement

•History of, or current pancreatitis

•History of, or current severe congestive heart failure, end-stage renal disease, hepatic disease

•History of, or current significant neurological condition (e.g., epilepsy)

•History of, or current significant thyroid disorder

•History (including family history) of, or current multiple endocrine neoplasia syndrome type-2 (MEN 2) or medullary thyroid carcinoma (MTC)

•Known type-1 or type-2 diabetes mellitus

•Known hypersensitivity to the study drug (i.e., semaglutide)

•Pregnant, breast feeding, or person of child-bearing potential not using appropriate contraceptive measures including hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomised partner, condom, absolute sexual abstinence - periodic sexual abstinence, withdrawal, and spermicides-only are not acceptable methods of contraception

•Participation in a study that uses the same or similar computer tasks (O-ETB, see below) as those used in the present study

•Participation in a study that involves the use of a medication within the last 3 months

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Energy/activity

Time frame:Across 6-7 days

descriptive

Other clinical outcomes

7 endpoints

Primary/protocol endpoint/low confidence

Reward (learning)

Time frame:6-7 days

change from baseline, improvement

Primary/protocol endpoint/low confidence

Reward (effort-based)

Time frame:6-7 days

descriptive

Primary/protocol endpoint/low confidence

Reward (primary)

Time frame:6-7 days

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Emotional processing

Time frame:6-7 days

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Emotional impulsivity

Time frame:6-7 days

change from baseline, improvement

Secondary/protocol endpoint

Memory (short- and medium-term) processing

Time frame:6-7 days

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Memory (working) processing

Time frame:6-7 days

change from baseline, improvement

Publications (16)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-Like Peptide-1 Receptor Agonists.
2026 Jan (month)PMID31855395via CT.gov background
Pramipexole Enhances Reward Learning by Preserving Value Estimates.
Biological psychiatry2024 Feb 1PMID37330165doi:10.1016/j.biopsych.2023.05.023via CT.gov background
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.
Pharmacological reports : PR2021 Aug (month)PMID34003475doi:10.1007/s43440-021-00274-8via CT.gov background
Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.
Psychopharmacology2021 May (month)PMID31938879doi:10.1007/s00213-019-05448-0via CT.gov background
A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.
Journal of affective disorders2019 Oct 1PMID31153593doi:10.1016/j.jad.2019.05.044via CT.gov background
Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression.
Experimental neurology2019 May (month)PMID30695707doi:10.1016/j.expneurol.2019.01.016via CT.gov background
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
Diabetes, obesity & metabolism2017 Nov (month)PMID28386912doi:10.1111/dom.12963via CT.gov background
How do antidepressants work? New perspectives for refining future treatment approaches.
The lancet. Psychiatry2017 May (month)PMID28153641doi:10.1016/S2215-0366(17)30015-9via CT.gov background
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
Journal of affective disorders2017 Jan 1PMID27721184doi:10.1016/j.jad.2016.09.056via CT.gov background
Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.
Primary care diabetes2016 Apr (month)PMID26137918doi:10.1016/j.pcd.2015.06.003via CT.gov background
Characterization of reward and effort mechanisms in apathy.
Journal of physiology, Paris2015 Feb-Jun (year)PMID24747776doi:10.1016/j.jphysparis.2014.04.002via CT.gov background
Effect of acute antidepressant administration on negative affective bias in depressed patients.
The American journal of psychiatry2009 Oct (month)PMID19755572doi:10.1176/appi.ajp.2009.09020149via CT.gov background
Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans.
Nature2006 Aug 31PMID16929307doi:10.1038/nature05051via CT.gov background
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
The American journal of psychiatry2004 Jul (month)PMID15229059doi:10.1176/appi.ajp.161.7.1256via CT.gov background
Taste and smell perception in depression.
Biological psychiatry1987 Dec (month)PMID3676376doi:10.1016/0006-3223(87)90108-9via CT.gov background
Age differences in short-term retention of rapidly changing information.
Journal of experimental psychology1958 Apr (month)PMID13539317doi:10.1037/h0043688via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.